Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: A prospectively observational study

• Published in: Chronic respiratory disease Vol. 17; p. 1479973120916184
• Main Authors: Li, Xiaolong, Wu, Zhen, Xue, Mingyue, Du, Wei
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 2020; Sage Publications Ltd
• Subjects: Aged; Blood Gas Analysis - methods; Carbon Dioxide - blood; China - epidemiology; Chronic obstructive pulmonary disease; Cough - diagnosis; Cough - etiology; Disease Progression; Dyspnea; Dyspnea - diagnosis; Dyspnea - etiology; Genotype & phenotype; Humans; Male; Middle Aged; Observational studies; Original Paper; Oxygen - blood; Pulmonary Disease, Chronic Obstructive - epidemiology; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary Disease, Chronic Obstructive - psychology; Pulmonary Disease, Chronic Obstructive - therapy; Respiratory failure; Respiratory Function Tests - methods; Respiratory Function Tests - statistics & numerical data; Severity of Illness Index; Smoking; Smoking - adverse effects; Smoking - blood; Smoking - physiopathology; Symptom Flare Up; Tobacco Smoke Pollution - adverse effects; Tobacco Smoke Pollution - analysis; Vital Capacity; China; phenotype; biomass; therapeutics; smoking; COPD
• ISSN: 1479-9731; 1479-9723; 1479-9731
• DOI: 10.1177/1479973120916184

Existing studies primarily explored chronic obstructive pulmonary disease (COPD) in smokers, whereas the clinical characteristics and the disease course of passive or nonsmokers have been rarely described. In the present study, patients hospitalized and diagnosed as acute exacerbation of COPD (AECOPD) were recruited and followed up until being discharged. Clinical and laboratory indicators were ascertained and delved into. A total of 100 patients were covered, namely, 52 active smokers, 34 passive smokers, and 14 nonsmokers. As revealed from the results here, passive or nonsmokers developed less severe dyspnea (patients with modified Medical Research Council scale (mMRC) <2, 0.0% vs. 8.8% vs. 14.3%, p < 0.05, active, passive, and nonsmokers, respectively), higher oxygenation index (206.4 ± 45.5 vs. 241.2 ± 51.1 vs. 242.4 ± 41.8 mmHg, p < 0.01), as well as lower arterial partial pressure of carbon dioxide (70.8 ± 12.7 vs. 58.85 ± 9.9 vs. 56.6 ± 6.5 mmHg, p < 0.001). Despite lower treatment intensity over these patients, amelioration of dyspnea, mitigation of cough, and elevation of oxygenation index were comparable to those of active smokers. However, in terms of patients exhibiting mMRC ≥2 and type 2 respiratory failure, amelioration of dyspnea was more common in nonsmokers as compared with passive smokers (46.4% vs. 83.3%, p < 0.05, passive and nonsmokers, respectively). In terms of patients exhibiting Global Initiative for COPD severity <3, mMRC ≥2, and type 2 respiratory failure, active smokers achieved the least mitigation of cough symptom (8.7% vs. 35.0% vs. 44.4%, p < 0.05). Similar results could be achieved after the effects of confounders were excluded, with the most prominent amelioration of dyspnea (odds ratio (OR) 3.8, 95% confidence interval (CI) 1.1–13.6, p < 0.05, as compared with active smokers) and cough (OR 3.3, 95% CI 1.0–10.7, p < 0.05) in nonsmokers, and relatively better amelioration of hypoxemia in passive smokers (oxygenation index change, 39.0 ± 34.6 vs. 51.5 ± 32.4 vs. 45.3 ± 25.4 mmHg, p < 0.05). In brief, passive or nonsmokers with AECOPD were subjected to less severe disease, and nonsmokers, especially patients with more severe disease, might achieve the optimal enhancement of clinical presentation after treatment.